Paul Boeke, MD
Ophthalmology · Hiawatha, IANPI 1447544192
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $2,403 of the $3,884 with a category attached, or 61.9%. US Retina LLC accounts for 61.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $1,333 and has fallen 71.9% since, to $374 in 2025.
Across 44 payments — averaging $88.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$2K
- Regeneron Healthcare Solutions, Inc.$370
- Alimera Sciences, Inc.$245
- Apellis Pharmaceuticals, Inc.$237
- US Oncology Corporate, Inc.$222
- Novartis$161
- plus $246 from 5 others
What the payments were for
- Food & beverage$1,48138%
- Ownership interest$2,40362%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 5 | $2,403 |
| Regeneron Healthcare Solutions, Inc. | 14 | $370 |
| Alimera Sciences, Inc. | 1 | $245 |
| Apellis Pharmaceuticals, Inc. | 8 | $237 |
| US Oncology Corporate, Inc. | 1 | $222 |
| Novartis | 3 | $161 |
| AbbVie(2 entities) | 4 | $74 |
| Bausch & Lomb Americas Inc. | 3 | $64 |
| Genentech USA, Inc. | 3 | $57 |
| Amgen | 1 | $35 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,884 in reported general payments places this provider in the 75th percentile of 172 ophthalmology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 246 | $10,846 |
| MoxifloxacinMoxifloxacin Hcl | 72 | $1,557 |
| Ketorolac Tromethamine | 60 | $1,282 |
| Atropine Sulfate | 36 | $1,161 |
| Latanoprost | 52 | $616 |
| Timolol Maleate | 49 | $390 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 48 | $347 |
| Eplerenone | 12 | $236 |
| Ciprofloxacin Hcl | 11 | $214 |
| Dorzolamide Hcl | 18 | $185 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Hiawatha
- Edward HuHiawatha$160K
- Caroline WilsonHiawatha$14K
- Michael AbramoffIowa City$158K
- Stephen RussellIowa City$137K
- Jared NielsenWest Des Moines$117K
- Matthew RauenWest Des Moines$108K
- Jason JonesSioux City$83K
- Christy BensonDes Moines$70K
- Alina DumitrescuIowa City$57K
- Keith CarterIowa City$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.